Figure D3, Informational letter for cardiovascular risk factors
Paul G Shekelle(VA Greater Los Angeles Healthcare System), Chantelle Garritty(Ottawa Hospital), Winifred W Yu(Tufts Medical Center), James M Gaylor(Tufts Medical Center), Marika J Suttorp, Sydne J Newberry, David Moher(University of Ottawa), Jounghee Lee(Tufts Medical Center), Rebecca Skidmore, Aneesa Motala(University of Southern California), Mohammed Ansari(University of Ottawa), Yee-Wei Lim(RAND Corporation), Ethan M. Balk(New York University), Helen Wu, Mei Chung
Unknown
June 1, 2011
Cited by 0
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
|BMJ|2010|9k
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
|Annals of Internal Medicine|2015|8.2k
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
|Annals of Internal Medicine|2003|4.6k
Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement
|Journal of Clinical Epidemiology|2021|2.8k